ClinicalTrials.Veeva

Menu

Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma (THT-CMM)

S

Sona Nanotech

Status

Completed

Conditions

Cutaneous Metastatic Melanoma

Treatments

Device: Device: Targeted Hyperthermia Therapy

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

This first-in-human device clinical trial investigates the safety and feasibility of GNR-mediated THT in patients with stage 3C/3D/4M1 cutaneous metastatic melanoma unresponsive to systemic to PD-1 immune checkpoint immunotherapy or in patients who have contraindications to systemic immunotherapy.

The primary objective of the study is to evaluate the safety and feasibility of THT treatment, with secondary objectives focused on tumor response to treatment.

Patients will receive intratumoral GNR injections, followed by NIR light therapy to induce mild hyperthermia, with intratumoral temperatures monitored to achieve a target range of 42°C to 48°C.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years of age or older
  • Participants with histologically or cytologically confirmed stage 3C/3D/4M1 advanced or cutaneous metastatic melanoma, with measurable disease by standard histological methods (not iRECIST) including any number of cutaneous lesions
  • Present a visible and accessible primary tumor or metastatic deposit (any site) that has not been surgically removed
  • Present target tumors of 0.5 -2.5 cm in diameter
  • Participants must have received and failed (progressed) following at least one prior standard therapy, including immune checkpoint inhibitors (e.g., anti- PD1 or anti-CTLA-4).
  • Response is determined by clinical assessment and photo documentation.
  • ECOG Performance Status: 0-1
  • Life expectancy: ≥6 months
  • Participants able and willing to provide written informed consent and comply with the trial protocol.

Exclusion criteria

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Women of childbearing potential must have a negative pregnancy test within 72 hours prior to enrollment and agree to use adequate contraception throughout the study
  • Any infection requiring systemic therapy or other concurrent medical conditions (e.g., hepatitis B, hepatitis C, HIV) that would interfere with the study
  • Myocardial infarction or stroke within the past 6 months, uncontrolled angina, or significant arrhythmia
  • Participants receiving blood thinners as part of therapeutic anticoagulation therapy
  • Any severe or uncontrolled comorbid condition that, in the investigator's opinion, would pose excessive risk to the participants (e.g., immunodeficiencies, severe hypertension, uncontrolled diabetes, liver failure)
  • Participation in another clinical trial involving an investigational product/device within 30 days prior to screening
  • Any condition that would impede compliance with study procedures
  • Participants with a known allergy to gold of any kind
  • Participants who are unable to tolerate cutaneous injections for any reason will not be eligible
  • Participants with a known allergy to injectable local analgesics
  • Participants with ocular melanoma or melanoma involving periorbital skin.

Trial design

Primary purpose

Device Feasibility

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Targeted Hyperthermia Therapy
Experimental group
Treatment:
Device: Device: Targeted Hyperthermia Therapy

Trial contacts and locations

1

Loading...

Central trial contact

Carman Giacomantonio, MD; Len Len Pagliaro, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems